Optically Active Polycyclic Carbamoylpyridone Derivatives for HIV Integrase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-HIV drugs, particularly integrase inhibitors, face challenges such as resistance development, adverse reactions, and the need for long-acting formulations to improve patient quality of life and reduce medication frequency, with existing polycyclic carbamoylpyridone derivatives lacking optically active tricyclic or higher structures.
Innovation Solution
A novel optically active tricyclic or more polycyclic carbamoylpyridotriazine derivative with integrase inhibitory activity is developed, offering a high resistance barrier and potential as a long-acting anti-HIV drug with improved pharmacokinetics and safety profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing polycyclic carbamoylpyridone derivatives are used as integrase inhibitors, then antiviral activity is achieved, but resistance barrier is insufficient and adverse reactions occur
Solution Approach 1:
The patent introduces optically active centers into the polycyclic carbamoylpyridone derivative structure, creating enantiomers with improved pharmacological properties. This chiral modification changes the spatial configuration parameters of the molecule, enhancing its binding selectivity to HIV integrase while reducing off-target effects that cause adverse reactions and resistance development.
Solution Approach 2:
The invention combines multiple heterocyclic rings (pyridone, triazine, and additional aromatic or heteroaromatic rings) into a fused polycyclic system with specific substitution patterns. This composite structural approach creates a more complex molecular architecture that improves integrase inhibition potency and resistance barrier compared to simpler bicyclic analogs.
2Reliability
If frequent injections are administered to achieve therapeutic effect, then antiviral activity is maintained, but patient quality of life deteriorates due to medication fatigue
Solution Approach 1:
The patent develops long-acting injectable formulations that extend the dosing interval from frequent administrations to once-monthly or once-quarterly injections. The optimized pharmacokinetic properties of the optically active derivatives enable sustained therapeutic levels over extended periods, reducing medication frequency while maintaining antiviral efficacy and improving patient compliance.
3Reliability
If multiple injection sites are used to administer long-acting injections, then therapeutic coverage is improved, but patient discomfort increases due to pain
Solution Approach 1:
The patent formulates the optically active carbamoylpyridone derivative as a single long-acting injectable preparation that can be administered at one injection site. The extended-release formulation consolidates the therapeutic function into one injection, eliminating the need for multiple injection sites while maintaining adequate therapeutic coverage and reducing patient discomfort.
4Adaptability or versatility
If dolutegravir is used to treat patients with first-generation integrase inhibitor resistance, then treatment option is provided, but further resistance mutations may develop reducing effectiveness
Solution Approach 1:
The patent creates novel optically active polycyclic carbamoylpyridone derivatives with modified molecular structures that confer a higher resistance barrier. These compounds exhibit different binding characteristics to HIV integrase compared to existing drugs, allowing them to remain effective against strains resistant to first- and second-generation integrase inhibitors, thus providing treatment flexibility while maintaining long-term effectiveness.
Data Source
AI summary
The present invention provides a compound represented by Formula (I):wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R1 is halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.